For a newly diagnosed type 2 patient with an elevated A1c of 7-8%, would you consider an SGLT-2 drug as a second treatment option added to metformin if they are not at goal on metformin? Follow the link to share your opinion and see what your colleagues think!

When we were at the recent CES show in Las Vegas, the health and fitness categories had their own hall in the convention center. This is quite a change from 5 yeas ago when you only had one health related exhibitor. One of the other fast growing areas is combining …

New research finds issue in the setting of dehydration and/or during use of nonsteroidal anti-inflammatory agents (NSAIDs) or radiocontrast studies.

Investigation supports that early diabetes has lower thromboembolic risk than later.

Survey estimates that diabetes accounts for many more deaths in the United States than are being reported on death certificates — and that diabetes is actually the third leading cause of death.

Phase-3 study to evaluate efficacy and safety of ertugliflozin monotherapy.

A new study suggests that people who spend time walking or even just standing instead of sitting may be at lower risk of type 2 diabetes.

As an exercise physiologist, I first and foremost focus on the physical activity part for management of blood glucose levels, often stating that being active will increase insulin action, lower blood glucose levels, and make diabetes management easier. In reality, not all of those benefits are fully evident in many cases. In fact, they usually cannot be counted on unless you take into account myriad other factors that can have an equally—if not more—dramatic effect on blood glucose management.

Hypoglycemia is a potential side effect of which of the following classes of drugs: 1) Insulins 2) Sulfonylureas 3) Meglitinides 4) Amylin mimetics 5) All of the above Follow the link to see the right answer!